Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast as adjunct to antidepressants in MDD
NCT04751071Phase 2Withdrawn
- Sponsor
- Sadat City University
- Start
- Feb 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast in major depressive disorder (MDD), sponsored by Sadat City University. Planned start Feb 2021; status: withdrawn.
02
Drugs
roflumilast
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04751071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751071.